Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822017 | 0.95 | NTRK1 (0.51) | NTRK1ACHEKDM4EPOLBGUSB | |
| SCHEMBL7811355 | 0.90 | NTRK1 (0.50) | NTRK1ACHEKDM4EPOLBGUSB | |
| SCHEMBL3738396 | 0.87 | ALOX15 (0.43) | KDM4EPOLBGUSBMEN1KMT2A | |
| SCHEMBL3733796 | 0.85 | GUSB (0.52) | NTRK1ACHEKDM4EPOLBGUSB | |
| SCHEMBL7820788 | 0.84 | USP8 (0.42) | NTRK1ACHEKDM4EKMT2AL3MBTL1 | |
| SCHEMBL3746316 | 0.84 | AMY1A (0.41) | NTRK1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL16895274 | 0.82 | APAF1 (0.48) | ACHEKDM4EGUSBMEN1KMT2A | |
| SCHEMBL7464693 | 0.81 | ACHE (0.51) | NTRK1ACHEKDM4EPOLBGUSB | |
| SCHEMBL7820175 | 0.81 | TP53 (0.51) | ACHEKDM4EPOLBMEN1KMT2A | |
| SCHEMBL7825423 | 0.81 | TP53 (0.51) | KDM4EPOLBMEN1KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | NTRK1 4732/4885ACHE 865/4885KDM4E 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.